1 |
Xiao J, Tian W, Abdullah, Wang H, Chen M, Huang Q, Zhang M, Lu M, Song M, Cao Y. Updated design strategies for oral delivery systems: maximized bioefficacy of dietary bioactive compounds achieved by inducing proper digestive fate and sensory attributes. Crit Rev Food Sci Nutr 2022;:1-20. [PMID: 35959723 DOI: 10.1080/10408398.2022.2109583] [Reference Citation Analysis]
|
2 |
Cai L, Xu X, Chen W. The Current State of the Art in PARP Inhibitor-Based Delivery Nanosystems. Pharmaceutics 2022;14:1647. [DOI: 10.3390/pharmaceutics14081647] [Reference Citation Analysis]
|
3 |
Quach T, Hu L, Han S, Lim SF, Senyschyn D, Yadav P, Trevaksis NL, Simpson JS, Porter CJH. Triglyceride-Mimetic Prodrugs of Buprenorphine Enhance Oral Bioavailability via Promotion of Lymphatic Transport. Front Pharmacol 2022;13:879660. [DOI: 10.3389/fphar.2022.879660] [Reference Citation Analysis]
|
4 |
Yoshida T, Kojima H, Sako K, Kondo H. Drug delivery to the intestinal lymph by oral formulations. Pharm Dev Technol 2022;:1-61. [PMID: 35037843 DOI: 10.1080/10837450.2022.2030353] [Reference Citation Analysis]
|